Tesamorelin 10mg

Tesamorelin (CAS 218949-48-9, MW ~5135 Da) is a synthetic GHRH analogue — the full 44-amino acid sequence of endogenous GHRH with a trans-3-hexenoic acid group at the N-terminus to improve DPP-IV resistance. It stimulates pituitary GHRH receptors to produce pulsatile GH release, which in turn increases hepatic IGF-1 production. Research has focused primarily on visceral adipose tissue reduction via GH-stimulated lipolysis, with significant clinical evidence from lipodystrophy trials. Secondary research areas include body recomposition, GH/IGF-1 axis characterisation, and emerging cognitive function data. For research use only.

Tesamorelin and GLP-1 compounds operate through entirely different mechanisms. GLP-1 agonists (semaglutide, tirzepatide, Retatrutide) suppress appetite via hypothalamic/vagal pathways and directly activate metabolic receptors to reduce food intake. Tesamorelin stimulates the pituitary to produce more growth hormone — it does not suppress appetite or act on GLP-1, GIP, or glucagon receptors. The downstream effect on fat loss occurs via GH-stimulated lipolysis rather than caloric restriction. In research, Tesamorelin is particularly studied for visceral fat without the appetite suppression mechanism, making it a distinct tool from the GLP-1 class. Not for human consumption — for research use only.

Both Tesamorelin and CJC-1295 (no DAC) are GHRH analogues that stimulate pulsatile GH release. Key differences: Tesamorelin is the full 44-amino acid GHRH sequence with N-terminal fatty acid modification — most closely resembling endogenous GHRH in structure. CJC-1295 is a truncated 29-amino acid GHRH fragment with four amino acid substitutions. Tesamorelin is preferred when GHRH receptor fidelity to the full endogenous sequence is a research requirement. CJC-1295 is more commonly used in combination protocols with Ipamorelin. Not for human consumption — for research use only.

Reconstitution: Draw 1–2mL of bacteriostatic water into a clean 31G insulin syringe. Inject slowly down the inside wall of the Tesamorelin vial. Gently swirl until fully dissolved — do not shake or vortex. The solution should be clear and colourless. Common concentration: 1mL BAC water = 10mg/mL. Storage: Lyophilised — store at −20°C for up to 24 months. Reconstituted — refrigerate at 2–8°C and use within 28 days. Protect from light throughout.

Tesamorelin is legal to purchase in Australia for legitimate laboratory research purposes. It is not listed as a scheduled substance under the Poisons Standard when sold for research use only. Purchasers must be 18+ and confirm research-only use. It is not TGA-approved for human consumption, therapeutic, or veterinary use. Our Tesamorelin 10mg is independently verified at 99.1% HPLC purity with full COA documentation. Peptide Warehouse dispatches nationwide from our Melbourne warehouse via Australia Post.

Peptide Warehouse stocks research-grade Tesamorelin 10mg and dispatches nationwide via Australia Post with full tracking from our Melbourne warehouse. Orders placed before 11PM AEST dispatch the next business day. Standard Post (2–6 business days) $9.99; Express Post (1–3 business days) $15.99. Free shipping on orders over $199 AUD. Discreet plain packaging. For dual-pathway GH secretagogue research, also see our [CJC-1295 + Ipamorelin Blend](/products/cjc-1295-ipamorelin-10mg).

Tesamorelin has CAS number 218949-48-9 and an approximate molecular weight of 5135 Da. It is the full 44-amino acid sequence of endogenous GHRH(1-44) with a trans-3-hexenoic acid group conjugated to the N-terminal tyrosine residue. This modification improves DPP-IV resistance while preserving GHRH receptor binding affinity. Identity is confirmed in our batches via mass spectrometry as documented in the COA. Not for human consumption — for research use only.